Lu, Dai individual record
Associate Professor

The Lu laboratory is a medicinal chemistry laboratory working in the interface of organic chemistry and pharmaceutical sciences. The lab is engaged in the discovery of potential therapeutics for the treatment of cancer, neurodegenerative diseases and various disorders associated with the endocannabinoid system such as pain, drug-addiction and obesity. The current research projects in the Lu lab include the synthesis of water-soluble analogs of natural products such as taxanes and cannabinoids; the synthesis of various pharmacologically important cannabinoid ligands including agonists, inverse agonists, and allosteric modulators; the synthesis of novel protein kinase inhibitors to regulate the Abelson kinases (ABLs) and cyclin dependent kinases (CDKs). The Lu lab is also interested in the preparation and fabrication of multi-drug-loaded nanoparticles to tackle the deadly pancreatic cancer. These research projects have been funded by National Institute of Health and the State of Texas. Dr. Lu's contributions in medicinal chemistry include the discovery of the first type of intrinsically fluorescent ligands for the G-protein-coupled receptor CB1 and CB2, the discovery of one of the first two selective agonists for the CB2 cannabinoid receptor, the discovery of water-soluble cannabinoids, the discovery of a novel class of protein kinase inhibitors, and the discovery of a clinical drug candidate Buagafuran.

education and training
selected publications
Academic Articles34
  • Fu, B., Li, Y., Peng, S., Wang, X., Hu, J., Lv, L., ... Qin, C. (2021). Synthesis and pharmacological characterization of glucopyranosyl-conjugated benzyl derivatives as novel selective cytotoxic agents against colon cancer.. R Soc Open Sci. 8(2), 201642.
    doi badge pubmed badge
  • Khuroo, T., Dharani, S., Mohamed, E. M., Immadi, S., Wu, Z., Khan, M. A., ... Rahman, Z. (2021). Ultra-long acting prodrug of dolutegravir and delivery system Physicochemical, pharmacokinetic and formulation characterizations. International Journal of Pharmaceutics. 120889.
    doi badge
  • Mustafa, M., Donvito, G., Moncayo, L., Swafford, A., Poklis, J., Grauer, R., ... Lichtman, A. H. (2020). In vivo evaluation of the CB1 allosteric modulator LDK1258 reveals CB1-receptor independent behavioral effects.. Pharmacol Biochem Behav. 190, 172840-172840.
    doi badge pubmed badge
  • Lu, D., Immadi, S. S., Wu, Z., & Kendall, D. A. (2019). Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor.. Acta Pharmacol Sin. 40(3), 324-335.
    doi badge pubmed badge
  • Jagla, C., Scott, C. E., Tang, Y., Qiao, C., Mateo-Semidey, G. E., Yudowski, G. A., Lu, D., & Kendall, D. A. (2019). Pyrimidinyl Biphenylureas Act as Allosteric Modulators to Activate Cannabinoid Receptor 1 and Initiate β-Arrestin-Dependent Responses.. Mol Pharmacol. 95(1), 1-10.
    doi badge pubmed badge
  • Lu, D., & Potter, D. E. (2017). Cannabinoids and the Cannabinoid Receptors: An Overview. Handbook of Cannabis and Related Pathologies. 553-563. Elsevier.
    doi badge
Conference Papers1
  • Wu, Z., Fu, B., Qiao, C., Nagaraju, A., & Lu, D. (2018). Abstract 1661: Discovery of potent Abelson kinase inhibitors from the scaffold of pyrano[2,3-d]pyrimidin-7-one. Cancer Chemistry, Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. 78(13), 1661-1661.
    doi badge
recent teaching activities
First Name
Last Name
mailing address
1010 West Avenue B;
Kingsville, TX 78363